Genmab A/S $GMAB reported second-quarter 2026 revenue of $1.2 billion, up 24.9% from a year earlier, as gross profit rose to $1.1 billion. Operating profit increased modestly to $375 million, while cost of sales climbed to $84 million.
Net income attributable to common shareholders was $303 million, down 9.8% from the prior-year quarter. Diluted earnings per share came in at $0.49, and cash from operating activities fell sharply to $51 million.
On the balance sheet, Genmab ended the period with $1.5 billion in cash and cash equivalents, while total liabilities increased to $6.6 billion. Capital spending remained light, with purchases of property, plant and equipment at just $2 million.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Genmab A/S Hedge Fund Activity
We have seen 137 institutional investors add shares of Genmab A/S stock to their portfolio, and 156 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 3,663,250 shares (+inf%) to their portfolio in Q1 2026, for an estimated $98,284,997
- ORBIS ALLAN GRAY LTD removed 1,492,884 shares (-10.4%) from their portfolio in Q1 2026, for an estimated $40,054,077
- TWO SIGMA INVESTMENTS, LP added 1,443,589 shares (+161.1%) to their portfolio in Q1 2026, for an estimated $38,731,492
- ALLIANCEBERNSTEIN L.P. removed 1,319,945 shares (-12.1%) from their portfolio in Q1 2026, for an estimated $35,414,124
- FRANKLIN RESOURCES INC added 1,162,495 shares (+3792.8%) to their portfolio in Q1 2026, for an estimated $31,189,740
- FIRST TRUST ADVISORS LP added 1,126,069 shares (+84.3%) to their portfolio in Q1 2026, for an estimated $30,212,431
- PARADIGM BIOCAPITAL ADVISORS LP added 928,002 shares (+13.2%) to their portfolio in Q1 2026, for an estimated $24,898,293
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Genmab A/S Congressional Stock Trading
Members of Congress have traded $GMAB stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GMAB stock by members of Congress over the last 6 months:
- SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Genmab A/S Analyst Ratings
Wall Street analysts have issued reports on $GMAB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/18/2026
To track analyst ratings and price targets for Genmab A/S, check out Quiver Quantitative's $GMAB forecast page.
Genmab A/S Price Targets
Multiple analysts have issued price targets for $GMAB recently. We have seen 6 analysts offer price targets for $GMAB in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $40.0 on 07/02/2026
- Kalpit Patel from Wolfe Research set a target price of $32.0 on 03/27/2026
- Eva Fortea Verdejo from Wells Fargo set a target price of $40.0 on 03/02/2026
- Michael Schmidt from Guggenheim set a target price of $40.0 on 02/23/2026
- Benjamin Jackson from Jefferies set a target price of $41.5 on 02/17/2026
- Judah Frommer from Morgan Stanley set a target price of $34.0 on 02/16/2026
